Why talk of a pharma patent deal-making surge in 2018 is premature
A flurry of pharmaceuticals transactions in January has led several observers to describe the past month as the best start to M&A in recent years, and has further encouraged predictions of a surge in patent-driven acquisitions in 2018.
Yet, by a…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.